Abstract
This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4-9 |
| Number of pages | 6 |
| Journal | Oncology (Williston Park, N.Y.) |
| Volume | 21 |
| Issue number | 11 Suppl 5 |
| State | Published - Oct 2007 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. / Mitchell, Edith P.; Perez-Soler, Roman; Van Cutsem, Eric; Lacouture, Mario E.
In: Oncology (Williston Park, N.Y.), Vol. 21, No. 11 Suppl 5, 10.2007, p. 4-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
AU - Mitchell, Edith P.
AU - Perez-Soler, Roman
AU - Van Cutsem, Eric
AU - Lacouture, Mario E.
PY - 2007/10
Y1 - 2007/10
N2 - This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.
AB - This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=38549149740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38549149740&partnerID=8YFLogxK
M3 - Article
C2 - 18154212
AN - SCOPUS:38549149740
VL - 21
SP - 4
EP - 9
JO - Oncology
JF - Oncology
SN - 0890-9091
IS - 11 Suppl 5
ER -